PE20131141A1 - Anticuerpo monoclonal - Google Patents
Anticuerpo monoclonalInfo
- Publication number
- PE20131141A1 PE20131141A1 PE2013000112A PE2013000112A PE20131141A1 PE 20131141 A1 PE20131141 A1 PE 20131141A1 PE 2013000112 A PE2013000112 A PE 2013000112A PE 2013000112 A PE2013000112 A PE 2013000112A PE 20131141 A1 PE20131141 A1 PE 20131141A1
- Authority
- PE
- Peru
- Prior art keywords
- amylomended
- peptides
- antibody
- seq
- amylohermede
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
SE REFIERE A UN ANTICUERPO MONOCLONAL QUE INCLUYE CUALQUIER ANTICUERPO FUNCIONALMENTE EQUIVALENTE O SUS PARTES FUNCIONALES, QUE RECONOCE UN EPITOPE CONFORMACIONAL, Y QUE SE UNE A PEPTIDOS Aß AMILOIDES SOLUBLES POLIMERICOS Y A PEPTIDOS Aß AMILOIDES OLIGOMERICOS QUE COMPRENDEN UNA PLURALIDAD DE PEPTIDOS Aß1-42 MONOMERICOS. DICHO ANTICUERPO COMPRENDE UN DOMINIO VARIABLE DE CADENA PESADA Y DE CADENA LIVIANA QUE EXHIBE UNA SECUENCIA DE AMINOACIDOS QUE ES DE 85% A 99% IDENTICAS A LA SEQ ID Nº7 Y SEQ ID Nº 8, O UNA PARTE FUNCIONAL DE ESTA QUE COMPRENDE UNA PARTE O LA TOTALIDAD DE LAS CDR DE CADENA LIVIANA Y DE CADENA PESADA QUE CONTIENEN LAS SECUENCIAS DE POLIPEPTIDOS SEQ ID Nº 9-14. SE REFIERE TAMBIEN A UN METODO DE PRODUCCION Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO SIENDO UTIL PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS CAUSADOS O ASOCIADOS A LAS PROTEINAS AMILOIDES O SIMILARES QUE INCLUYEN LA AMILOIDOSIS, ENFERMEDAD DE ALZHEIMER, SINDROME DE DOWN.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94354107P | 2007-06-12 | 2007-06-12 | |
US94354307P | 2007-06-12 | 2007-06-12 | |
US94379007P | 2007-06-13 | 2007-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20131141A1 true PE20131141A1 (es) | 2013-10-14 |
Family
ID=39790376
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013000112A PE20131141A1 (es) | 2007-06-12 | 2008-06-12 | Anticuerpo monoclonal |
PE2008001009A PE20090831A1 (es) | 2007-06-12 | 2008-06-12 | Anticuerpo monoclonal |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001009A PE20090831A1 (es) | 2007-06-12 | 2008-06-12 | Anticuerpo monoclonal |
Country Status (19)
Country | Link |
---|---|
EP (2) | EP2170953B1 (es) |
JP (2) | JP5436414B2 (es) |
KR (2) | KR20160017126A (es) |
CN (1) | CN101802007B (es) |
AR (1) | AR066987A1 (es) |
AU (1) | AU2008267037B2 (es) |
BR (1) | BRPI0812484A2 (es) |
CA (1) | CA2690434C (es) |
CL (3) | CL2008001742A1 (es) |
ES (1) | ES2548102T3 (es) |
HK (1) | HK1140500A1 (es) |
IL (1) | IL202563A (es) |
MX (1) | MX2009013503A (es) |
NZ (2) | NZ601843A (es) |
PE (2) | PE20131141A1 (es) |
RU (1) | RU2571856C2 (es) |
TW (2) | TWI453217B (es) |
WO (1) | WO2008156621A1 (es) |
ZA (1) | ZA201000049B (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
AP2007003890A0 (en) | 2004-07-30 | 2007-02-28 | Rinat Neuroscience Corp | Antibodies directed against amy-loid-beta peptide and methods using same |
CN102898519B (zh) | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
EP2289909B1 (en) | 2005-11-30 | 2014-10-29 | AbbVie Inc. | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
CA2657681C (en) | 2006-07-14 | 2019-03-19 | Ac Immune S.A. | Humanized antibodies against beta amyloid protein |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
CN101802007B (zh) * | 2007-06-12 | 2017-08-25 | Ac免疫有限公司 | 抗β淀粉样蛋白单克隆抗体 |
EP2238166B1 (en) * | 2007-10-05 | 2013-11-27 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
AR080446A1 (es) | 2010-03-03 | 2012-04-11 | Boehringer Ingelheim Int | Polipeptidos de union a a-beta (beta amiloide) |
WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
EP2598882B1 (en) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
ES2631356T3 (es) | 2010-11-30 | 2017-08-30 | F. Hoffmann-La Roche Ag | Anticuerpos anti-receptor de transferrina de baja afinidad y su uso para transferir scFv terapéuticos a través de la barrera hematoencefálica |
JP5991535B2 (ja) | 2011-02-18 | 2016-09-14 | 国立大学法人東京農工大学 | アミロイドタンパク質オリゴマー結合アプタマー |
CN102921007B (zh) * | 2011-08-09 | 2014-12-10 | 中国科学院上海生命科学研究院 | 防治胰岛素抵抗和糖尿病的方法和试剂 |
CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
MX2014014166A (es) | 2012-05-21 | 2015-03-03 | Genentech Inc | Metodos para mejorar la seguridad del transporte de la barrera hematoencefalica. |
JP6612214B2 (ja) | 2013-05-20 | 2019-11-27 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及び使用方法 |
SG11201601823TA (en) | 2013-09-13 | 2016-04-28 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
JP6779876B2 (ja) | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
AU2016353553B2 (en) | 2015-11-09 | 2022-01-20 | The University Of British Columbia | Amyloid beta epitopes and antibodies thereto |
EP3374381A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | EPITAOPES IN THE CENTRAL REGION OF BETA-AMYLOID AND RELATED CONFORMATIONAL ANTIBODIES |
WO2017184895A2 (en) * | 2016-04-20 | 2017-10-26 | Aelan Cell Technologies, Inc. | Compositions and methods related to κ180 dimethylated h1.0 protein |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
WO2020025066A1 (en) * | 2018-08-03 | 2020-02-06 | The University Of Hong Kong | Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli |
KR101977410B1 (ko) * | 2018-08-22 | 2019-05-10 | 주식회사 피플바이오 | 당뇨병에 대한 신규 바이오마커 및 그의 용도 |
CN111518205B (zh) * | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
CN111518206B (zh) * | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
EP3757125A1 (en) * | 2019-06-28 | 2020-12-30 | BioArctic AB | Antibody directed against the apoe amino-terminal fragment of 12 kda |
CN110317814A (zh) * | 2019-07-19 | 2019-10-11 | 莫丁丁 | β-淀粉样蛋白环状核糖核酸、多肽及其应用 |
EP4028127A1 (en) * | 2019-09-10 | 2022-07-20 | AC Immune SA | Novel molecules for diagnosis |
CN110687035A (zh) * | 2019-10-10 | 2020-01-14 | 沈阳万类生物科技有限公司 | Annexin V-Light 650凋亡检测试剂盒 |
CN113884683A (zh) * | 2020-07-30 | 2022-01-04 | 山东京济生物工程有限公司 | 一种快速检测Aβ42的双抗体夹心ELISA试剂盒 |
CN113308439B (zh) * | 2020-11-06 | 2023-05-05 | 华中科技大学 | 分泌人淀粉样蛋白-β单克隆抗体的杂交瘤细胞株及其应用 |
CN112540180B (zh) * | 2020-11-06 | 2022-03-29 | 华中科技大学 | 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒 |
CN113057963B (zh) * | 2021-03-31 | 2022-05-20 | 华中科技大学 | 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用 |
CN113311153B (zh) * | 2021-05-12 | 2023-05-26 | 华中科技大学 | 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子 |
CN113603773B (zh) * | 2021-08-17 | 2023-05-09 | 中国医科大学附属第一医院 | 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用 |
CN114591429B (zh) * | 2022-05-07 | 2022-08-09 | 北京第一生物化学药业有限公司 | 结合β-淀粉样蛋白的抗体及其用途 |
KR102565471B1 (ko) * | 2022-08-04 | 2023-08-10 | 가천대학교 산학협력단 | 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물 |
KR102565470B1 (ko) * | 2022-08-04 | 2023-08-10 | 가천대학교 산학협력단 | 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물 |
CN117586370A (zh) * | 2022-08-09 | 2024-02-23 | 深圳智源生物医药有限公司 | 强毒性淀粉样蛋白寡聚体及其用途 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
WO1994002178A1 (en) | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
ZA938243B (en) * | 1992-11-12 | 1995-05-04 | Hybritech Inc | Altered affinity polypeptides of metal chelate binding antibodies |
CA2127476C (en) | 1994-07-06 | 1999-12-07 | Daniel G. Pomerleau | Logging or measurement while tripping |
EP1076092A3 (en) | 1994-10-21 | 2001-03-28 | Innogenetics N.V. | Sequences of hepatitis C virus type10 and their use as prophylactic, therapeutic and diagnostic agents |
US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
JP3495738B2 (ja) * | 1995-09-14 | 2004-02-09 | ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 天然PrPsc特異的抗体 |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
AU2001284703B2 (en) | 2000-08-03 | 2007-03-22 | Therapeutic Human Polyclonals Inc. | Production of humanized antibodies in transgenic animals |
AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
WO2003009815A2 (en) | 2001-07-25 | 2003-02-06 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
WO2003014162A1 (en) * | 2001-08-03 | 2003-02-20 | Medical & Biological Laboratories Co., Ltd. | ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY |
EP1448601A4 (en) * | 2001-11-02 | 2006-04-26 | Diagenics Internat Corp | METHOD AND COMPOSITIONS OF MONOCLONAL ANTIBODIES SPECIFIC TO BETA-AMYLOIDE PROTEINS |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
CA2507762C (en) | 2002-12-03 | 2013-02-05 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
NZ541282A (en) | 2002-12-24 | 2009-02-28 | Bellus Health International Ltd | Therapeutic formulations for the treatment of beta-amyloid related diseases |
WO2004065569A2 (en) * | 2003-01-23 | 2004-08-05 | The Regents Of The University Of California | Multi-functional antibodies |
DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US8663650B2 (en) * | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
JP4870348B2 (ja) * | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | 細胞表面抗原に対する抗体取得とその抗原同定 |
AP2007003890A0 (en) * | 2004-07-30 | 2007-02-28 | Rinat Neuroscience Corp | Antibodies directed against amy-loid-beta peptide and methods using same |
JP2008540417A (ja) * | 2005-05-05 | 2008-11-20 | メルク エンド カムパニー インコーポレーテッド | ペプチドコンジュゲート組成物およびアルツハイマー病の予防および治療のための方法 |
CN105017423B (zh) * | 2005-08-11 | 2019-06-04 | 阿皮·马托西安-罗杰斯 | 用于自身免疫性疾病治疗和诊断的TCR-V-β相关肽 |
ES2616316T3 (es) * | 2005-10-11 | 2017-06-12 | Amgen Research (Munich) Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos |
CN102898519B (zh) * | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
WO2007064919A2 (en) * | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CN101802007B (zh) * | 2007-06-12 | 2017-08-25 | Ac免疫有限公司 | 抗β淀粉样蛋白单克隆抗体 |
-
2008
- 2008-06-12 CN CN200880103203.6A patent/CN101802007B/zh active Active
- 2008-06-12 TW TW097122016A patent/TWI453217B/zh active
- 2008-06-12 EP EP08768370.2A patent/EP2170953B1/en active Active
- 2008-06-12 EP EP12167447.7A patent/EP2527366B1/en active Active
- 2008-06-12 NZ NZ601843A patent/NZ601843A/en unknown
- 2008-06-12 ES ES08768370.2T patent/ES2548102T3/es active Active
- 2008-06-12 AR ARP080102521A patent/AR066987A1/es not_active Application Discontinuation
- 2008-06-12 JP JP2010512181A patent/JP5436414B2/ja active Active
- 2008-06-12 CL CL2008001742A patent/CL2008001742A1/es unknown
- 2008-06-12 KR KR1020167002381A patent/KR20160017126A/ko not_active Application Discontinuation
- 2008-06-12 RU RU2010100354/10A patent/RU2571856C2/ru active
- 2008-06-12 TW TW103117223A patent/TWI516500B/zh active
- 2008-06-12 PE PE2013000112A patent/PE20131141A1/es active IP Right Grant
- 2008-06-12 AU AU2008267037A patent/AU2008267037B2/en active Active
- 2008-06-12 WO PCT/US2008/007317 patent/WO2008156621A1/en active Application Filing
- 2008-06-12 BR BRPI0812484A patent/BRPI0812484A2/pt not_active IP Right Cessation
- 2008-06-12 NZ NZ581835A patent/NZ581835A/xx unknown
- 2008-06-12 MX MX2009013503A patent/MX2009013503A/es active IP Right Grant
- 2008-06-12 KR KR1020107000699A patent/KR101600095B1/ko active IP Right Grant
- 2008-06-12 PE PE2008001009A patent/PE20090831A1/es active IP Right Grant
- 2008-06-12 CA CA2690434A patent/CA2690434C/en active Active
-
2009
- 2009-12-07 IL IL202563A patent/IL202563A/en active IP Right Grant
-
2010
- 2010-01-04 ZA ZA2010/00049A patent/ZA201000049B/en unknown
- 2010-07-19 HK HK10106970.9A patent/HK1140500A1/xx unknown
-
2012
- 2012-03-09 CL CL2012000631A patent/CL2012000631A1/es unknown
- 2012-07-04 CL CL2012001817A patent/CL2012001817A1/es unknown
-
2013
- 2013-12-10 JP JP2013254631A patent/JP2014087353A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20131141A1 (es) | Anticuerpo monoclonal | |
PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
DOP2016000335A (es) | Anticuerpos anti-tau humanizados | |
AR069130A1 (es) | Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento | |
PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
PE20171512A1 (es) | Anticuerpos anti-fap | |
PE20120532A1 (es) | ANTICUERPOS ANTI-ActRIIB | |
AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
PE20120170A1 (es) | Variantes de union a anti-albumina de suero mejoradas | |
PE20090359A1 (es) | Polipeptidos, dominios variables de anticuerpos y antagonistas | |
GEP20115324B (en) | Tweak binding antibodies | |
AR107290A1 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
AR083672A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
PE20140231A1 (es) | Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9) | |
CO6251325A2 (es) | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) | |
AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
PE20080035A1 (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
CR20190208A (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y | |
AR110751A1 (es) | Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con proteínas de unión al receptor del péptido inhibidor gástrico (gipr) | |
JP2016531546A5 (es) | ||
FI3452507T3 (fi) | Tau-immuunihoito | |
EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |